Table 5.

Odds Ratios and 95% Confidence Intervals of Quintiles of baPWV to Developing Hypertension During First Follow‐Up

Model	Variable	Total	Male	Female
Model1	baPWV_Q1	1.00	1.00	1.00
	baPWV_Q2	1.08 (0.68–1.72)	1.22 (0.68–2.19)	1.07 (0.51–2.25)
	baPWV_Q3	2.11 (1.37–3.24)	2.3 (1.34–3.95)	1.59 (0.79–3.19)
	baPWV_Q4	2.34 (1.52–3.6)	2.81 (1.63–4.83)	1.81 (0.92–3.58)
	baPWV_Q5	3.66 (2.31–5.8)	4.26 (2.48–7.31)	3.5 (1.8–6.84)
Model2	baPWV_Q1	1.00	1.00	1.00
	baPWV_Q2	1.24 (0.75–2.05)	1.43 (0.77–2.67)	0.94 (0.41–2.18)
	baPWV_Q3	2.13 (1.33–3.41)	2.64 (1.48–4.71)	1.21 (0.54–2.72)
	baPWV_Q4	2.58 (1.63–4.08)	3.12 (1.75–5.57)	1.6 (0.74–3.44)
	baPWV_Q5	4.41 (2.82–6.89)	4.17 (2.36–7.38)	3.32 (1.59–6.93)

Abbreviations: baPWV, brachial‐ankle pulse wave velocity; Q, quartile. The initial variables for stepwise logistic regression include pulse wave velocity (Q1–Q5), systolic blood pressure (Q1–Q5), diastolic blood pressure (Q1–Q5), mean arterial pressure (Q1–Q5), pulse pressure (Q1–Q5), age, sex, height, body mass index, postmenopausal, current smoker, current alcohol drinkers, exercise, high salt iintake, hypoglycemic agents, antihypertensive agents, lipid‐lowering agents, heart rate, high‐density lipoprotein cholesterol, low‐density lipoprotein cholesterol, total cholesterol, triglyceride, serum creatinine, fasting glucose, C‐reactive protein, homocysteic acid, uric acid, and time to first follow‐up. Model 1: analysis on 432 newly diagnosed hypertensive patients. Model 2: analysis on 365 newly diagnosed nondrug‐treated hypertensive patients.